FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2725630963> ?p ?o ?g. }

• W2725630963 endingPage "74" @default.
• W2725630963 startingPage "66" @default.
• W2725630963 abstract "Summary Panobinostat in combination with bortezomib and dexamethasone demonstrated a significant and clinically meaningful progression‐free survival benefit compared with placebo, bortezomib and dexamethasone in the phase 3 PANORAMA 1 (Panobinostat Oral in Multiple Myeloma 1) trial. Despite this benefit, patients in the panobinostat arm experienced higher rates of adverse events ( AE s) and higher rates of discontinuation due to AE s. This PANORAMA 1 subanalysis examined AE s between 2 treatment phases of the study ( TP 1 and TP 2), in which administration frequency of bortezomib and dexamethasone differed per protocol. The incidences of several key AE s were lower in both arms following the planned reduction of bortezomib dosing frequency in TP 2. In the panobinostat arm, rates of thrombocytopenia (grade 3/4: TP 1, 56·7%; TP 2, 6·0%), diarrhoea (grade 3/4: TP 1, 24·1%; TP 2, 7·1%), and fatigue (grade 3/4: TP 1, 16·3%; TP 2, 1·8%) were lower in TP 2 compared with TP 1. Dose intensity analysis of panobinostat and bortezomib by cycle in the panobinostat arm showed reductions of both agent doses during cycles 1–4 due to dose adjustments for AE s. Exposure‐adjusted analysis demonstrated a reduction in thrombocytopenia frequency in TP 1 following dose adjustment. These results suggest that optimization of dosing with this regimen could improve tolerability, potentially leading to improved patient outcomes." @default.
• W2725630963 created "2017-07-14" @default.
• W2725630963 creator A5000672264 @default.
• W2725630963 creator A5002857933 @default.
• W2725630963 creator A5004781025 @default.
• W2725630963 creator A5011827756 @default.
• W2725630963 creator A5016360607 @default.
• W2725630963 creator A5020989412 @default.
• W2725630963 creator A5023276777 @default.
• W2725630963 creator A5027328800 @default.
• W2725630963 creator A5027919726 @default.
• W2725630963 creator A5030583882 @default.
• W2725630963 creator A5032960925 @default.
• W2725630963 creator A5034186877 @default.
• W2725630963 creator A5035748455 @default.
• W2725630963 creator A5043339826 @default.
• W2725630963 creator A5043526996 @default.
• W2725630963 creator A5043829360 @default.
• W2725630963 creator A5044268319 @default.
• W2725630963 creator A5046565118 @default.
• W2725630963 creator A5067657650 @default.
• W2725630963 creator A5074020738 @default.
• W2725630963 creator A5080776694 @default.
• W2725630963 creator A5089930850 @default.
• W2725630963 date "2017-06-27" @default.
• W2725630963 modified "2023-10-11" @default.
• W2725630963 title "Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial" @default.
• W2725630963 cites W1988265934 @default.
• W2725630963 cites W2007514736 @default.
• W2725630963 cites W2010028880 @default.
• W2725630963 cites W2018079029 @default.
• W2725630963 cites W2023351948 @default.
• W2725630963 cites W2048722552 @default.
• W2725630963 cites W2052169053 @default.
• W2725630963 cites W2065327255 @default.
• W2725630963 cites W2066800926 @default.
• W2725630963 cites W2096367061 @default.
• W2725630963 cites W2132880072 @default.
• W2725630963 cites W2134902298 @default.
• W2725630963 cites W2140579395 @default.
• W2725630963 cites W2145412346 @default.
• W2725630963 cites W2145493193 @default.
• W2725630963 cites W2168980644 @default.
• W2725630963 cites W2169183166 @default.
• W2725630963 cites W2311936801 @default.
• W2725630963 doi "https://doi.org/10.1111/bjh.14821" @default.
• W2725630963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28653400" @default.
• W2725630963 hasPublicationYear "2017" @default.
• W2725630963 type Work @default.
• W2725630963 sameAs 2725630963 @default.
• W2725630963 citedByCount "16" @default.
• W2725630963 countsByYear W27256309632017 @default.
• W2725630963 countsByYear W27256309632018 @default.
• W2725630963 countsByYear W27256309632019 @default.
• W2725630963 countsByYear W27256309632020 @default.
• W2725630963 countsByYear W27256309632021 @default.
• W2725630963 countsByYear W27256309632022 @default.
• W2725630963 countsByYear W27256309632023 @default.
• W2725630963 crossrefType "journal-article" @default.
• W2725630963 hasAuthorship W2725630963A5000672264 @default.
• W2725630963 hasAuthorship W2725630963A5002857933 @default.
• W2725630963 hasAuthorship W2725630963A5004781025 @default.
• W2725630963 hasAuthorship W2725630963A5011827756 @default.
• W2725630963 hasAuthorship W2725630963A5016360607 @default.
• W2725630963 hasAuthorship W2725630963A5020989412 @default.
• W2725630963 hasAuthorship W2725630963A5023276777 @default.
• W2725630963 hasAuthorship W2725630963A5027328800 @default.
• W2725630963 hasAuthorship W2725630963A5027919726 @default.
• W2725630963 hasAuthorship W2725630963A5030583882 @default.
• W2725630963 hasAuthorship W2725630963A5032960925 @default.
• W2725630963 hasAuthorship W2725630963A5034186877 @default.
• W2725630963 hasAuthorship W2725630963A5035748455 @default.
• W2725630963 hasAuthorship W2725630963A5043339826 @default.
• W2725630963 hasAuthorship W2725630963A5043526996 @default.
• W2725630963 hasAuthorship W2725630963A5043829360 @default.
• W2725630963 hasAuthorship W2725630963A5044268319 @default.
• W2725630963 hasAuthorship W2725630963A5046565118 @default.
• W2725630963 hasAuthorship W2725630963A5067657650 @default.
• W2725630963 hasAuthorship W2725630963A5074020738 @default.
• W2725630963 hasAuthorship W2725630963A5080776694 @default.
• W2725630963 hasAuthorship W2725630963A5089930850 @default.
• W2725630963 hasBestOaLocation W27256309631 @default.
• W2725630963 hasConcept C104317684 @default.
• W2725630963 hasConcept C126322002 @default.
• W2725630963 hasConcept C126894567 @default.
• W2725630963 hasConcept C143998085 @default.
• W2725630963 hasConcept C185592680 @default.
• W2725630963 hasConcept C197934379 @default.
• W2725630963 hasConcept C2776364478 @default.
• W2725630963 hasConcept C2777288759 @default.
• W2725630963 hasConcept C2777478702 @default.
• W2725630963 hasConcept C2778305200 @default.
• W2725630963 hasConcept C2778375690 @default.
• W2725630963 hasConcept C2778715236 @default.
• W2725630963 hasConcept C2780225316 @default.
• W2725630963 hasConcept C2780401358 @default.
• W2725630963 hasConcept C55493867 @default.
• W2725630963 hasConcept C64927066 @default.

• next